NCT02658487View on ClinicalTrials.gov

Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

April 30, 2019

Study Completion Date

September 30, 2024

Conditions

Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia With Multilineage DysplasiaMyeloid SarcomaSecondary Acute Myeloid LeukemiaTherapy-Related Acute Myeloid LeukemiaTherapy-Related Myelodysplastic Syndrome

Interventions

DRUG

Cytarabine

Given IV

DRUG

Vosaroxin

Given IV

Trial Locations (3)

29425

Medical University of South Carolina Hollings Cancer Center, Charleston

37232

Vanderbilt-Ingram Cancer Center, Nashville

06520

Yale University, New Haven

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Vanderbilt-Ingram Cancer Center

OTHER

NCT02658487 - Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter